实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
4期
448-450
,共3页
张容榕%林琳%周泽强%刘爱学%冯天举
張容榕%林琳%週澤彊%劉愛學%馮天舉
장용용%림림%주택강%류애학%풍천거
非小细胞肺癌%化疗%贝伐单抗%血管内皮生长因子
非小細胞肺癌%化療%貝伐單抗%血管內皮生長因子
비소세포폐암%화료%패벌단항%혈관내피생장인자
Non-small cell lung cancer%Chemotherapy%Bevacizumab%Vascular endothelial growth factor
目的:探讨贝伐单抗联合培美曲塞及顺铂治疗晚期非小细胞肺癌的疗效。方法将46例非小细胞肺癌患者随机分为给予贝伐单抗联合培美曲塞+顺铂化疗的观察组和给予培美曲塞+顺铂化疗的对照组,观察化疗后肿瘤缓解情况、分期情况以及肿瘤内分泌指标。结果化疗后,观察组缓解有效率(56.52%)、疾病控制率(78.26%)、肿瘤分期均明显优于对照组(P<0.05);观察组VEGFA、VEGFB以及VEGFC的mRNA水平(62.4±8.4、44.8±6.2、57.2±6.2)pg/ml、蛋白水平(82.3±11.2、77.9±9.5、52.3±7.3)pg/ml均明显低于对照组(P<0.05)。结论贝伐单抗联合培美曲塞+顺铂化疗有助于提高缓解率和降低肿瘤分期,并降低血管内皮生长因子含量,具有积极的临床价值。
目的:探討貝伐單抗聯閤培美麯塞及順鉑治療晚期非小細胞肺癌的療效。方法將46例非小細胞肺癌患者隨機分為給予貝伐單抗聯閤培美麯塞+順鉑化療的觀察組和給予培美麯塞+順鉑化療的對照組,觀察化療後腫瘤緩解情況、分期情況以及腫瘤內分泌指標。結果化療後,觀察組緩解有效率(56.52%)、疾病控製率(78.26%)、腫瘤分期均明顯優于對照組(P<0.05);觀察組VEGFA、VEGFB以及VEGFC的mRNA水平(62.4±8.4、44.8±6.2、57.2±6.2)pg/ml、蛋白水平(82.3±11.2、77.9±9.5、52.3±7.3)pg/ml均明顯低于對照組(P<0.05)。結論貝伐單抗聯閤培美麯塞+順鉑化療有助于提高緩解率和降低腫瘤分期,併降低血管內皮生長因子含量,具有積極的臨床價值。
목적:탐토패벌단항연합배미곡새급순박치료만기비소세포폐암적료효。방법장46례비소세포폐암환자수궤분위급여패벌단항연합배미곡새+순박화료적관찰조화급여배미곡새+순박화료적대조조,관찰화료후종류완해정황、분기정황이급종류내분비지표。결과화료후,관찰조완해유효솔(56.52%)、질병공제솔(78.26%)、종류분기균명현우우대조조(P<0.05);관찰조VEGFA、VEGFB이급VEGFC적mRNA수평(62.4±8.4、44.8±6.2、57.2±6.2)pg/ml、단백수평(82.3±11.2、77.9±9.5、52.3±7.3)pg/ml균명현저우대조조(P<0.05)。결론패벌단항연합배미곡새+순박화료유조우제고완해솔화강저종류분기,병강저혈관내피생장인자함량,구유적겁적림상개치。
Objective To study the effect of bevacizumab combined with pemetrexed +cisplatin for advanced non-small cell lung cancer .Methods 46 non-small cell lung cancer patients were randomly divided into the observation group who received bevacizumab combined with pemetrexed +cisplatin,and the control group treated with pemetrexed +cisplatin.Tumor remis-sion,clinical stage and tumor endocrine index were observed .Results After chemotherapy,remission rate(56.52%),disease control rate(78.26%),tumor stage in the observation group were significantly better than those of the control group (P<0.05);mRNA and protein level of VEGFA ,VEGFB and VEGFC in the observation group were (62.4 ±8.4、44.8 ±6.2 and 57.2 ±6.2) pg/ml and(82.3 ±11.2、77.9 ±9.5、52.3 ±7.3)pg/ml,which were significantly lower than those of the control group (P<0.05).Conclusion Bevacizumab combined with pemetrexed +cisplatin can improve the remission rate ,degrade tumor stage, and decrease vascular endothelial growth factor level .It has positive clinical value .